Top

Published in:

01-10-2011 | Original Paper

High frequency microsatellite instability has a prognostic value in endometrial endometrioid adenocarcinoma, but only in FIGO stage 1 cases

Authors: Anita Steinbakk, Anais Malpica, Aida Slewa, Einar Gudlaugsson, Emiel A. M. Janssen, Mark Arends, Arnold Jan Kruse, Yu Yinhua, Weiwei Feng, Jan P. Baak

Published in: Cellular Oncology | Issue 5/2011

Abstract

Objectives

To analyze the prognostic value of microsatellite instability (MSI) in a population-based study of FIGO stage 1–4 endometrial endometrioid adenocarcinomas. Study Design: Survival analysis in 273 patients of MSI status and clinico-pathologic features. Using a highly sensitive pentaplex polymerase chain reaction to establish MSI status, cases were divided into microsatellite stable (MSS), MSI-low (MSI-L, 1 marker positive) and MSI-high (MSI-H, 2–5 markers positive).

Results

After 61 months median follow-up (1–209), 34 (12.5%) of the patients developed metastases but only 6.4% of the FIGO-1. MSI (especially as MSI-H versus MSS/MSI-Lcombined) was prognostic in FIGO-1 but not in FIGO2-4. The 5 and10 year recurrence-free survival rates were 98% and 95% in the MSS/MSI-L versus 85% and 73% in the MSI-H patients (P = 0.005).

Conclusions

MSI-H status assessed by pentaplex polymerase chain reaction is an indicator of poor prognosis in FIGO 1, but not in FIGO 2–4 endometrial endometrioid adenocarcinomas.

S. Pecorelli, Revised FIGO staging for carcinoma of the vulva, cervix and endometrium. Int J Gynaecol Obstet 105, 103–104 (2009)PubMedCrossRef

J.P. Baak, W. Snijders, B. Van Diermen, P.J. Van Diest, F.W. Diepenhorst, J. Benraadt, Prospective multicenter validation confirms the prognostic superiority of the endometrial carcinoma prognostic index in International Federation of gynecology and obstetrics stage 1 and 2 endometrial carcinoma. J Clin Oncol 21, 4214–21 (2003)PubMedCrossRef

H.W. Van der Putten, J.P. Baak, T.J. Koenders, P.H. Kurver, H.G. Stolk, L.A. Stolte, Prognostic value of quantitative pathologic features and DNA content in individual patients with stage I endometrial adenocarcinoma. Cancer 63, 1378–138 (1998)CrossRef

R.J. Zaino, S.G. Silverberg, H.J. Norris, B.N. Bundy, C.P. Morrow, T. Okagaki, The prognostic value of nuclear versus architectural grading in endometrial adenocarcinoma. A Gynecologic Oncology Group study. Int J Gynecol Pathol 13, 29–36 (1994)PubMedCrossRef

G. Peiró, J. Diebold, P. Lohse, G.B. Baretton, U. Löhrs, Microsatellite instability, loss of heterozygosity, and loss of hMLH1 and hMSH2 protein expression in endometrial carcinoma. Hum Pathol 3, 347–54 (2002)

S. Fiumicino, A. Ercoli, G. Ferrandina et al., Microsatellite instability is an independent indicator of recurrence in sporadic stage I-II endometrial adenocarcinoma. J Clin Oncol 19, 1008–14 (2001)PubMed

Y.F. Wong, T.K. Cheung, K.W. Lo et al., Detection of microsatellite instability in endometrial cancer: advantages of a panel of five mononucleotide repeats over the National Cancer Institute panel of markers. Carcinogenesis 27, 951–5 (2006)PubMedCrossRef

D. Black, R.A. Soslow, D.A. Levine et al., Clinicopathologic significance of defective DNA mismatch repair in endometrial carcinoma. J Clin Oncol 24, 1745–53 (2006)PubMedCrossRef

H.J. An, K.I. Kim, J.Y. Kim et al., Microsatellite instability in endometrioid type endometrial adenocarcinoma is associated with poor prognostic indicators. Am J Surg Pathol 31, 846–53 (2007)PubMedCrossRef

10.

N.D. MacDonald, H.B. Salvesen, A. Ryan, O.E. Iversen, L.A. Akslen, I.J. Jacobs, Frequency and prognostic impact of microsatellite instability in a large population-based study of endometrial carcinomas. Cancer Res 60, 1750–2 (2000)PubMed

11.

I. Zighelboim, P.J. Goodfellow, F. Gao et al., Microsatellite Instability and Epigenetic Inactivation of MLH1 and Outcome of Patients With Endometrial Carcinomas of the Endometrioid Type. J Clin Oncol 25, 2042–2048 (2007)PubMedCrossRef

12.

R. Muresu, M.C. Sini, A. Cossu et al., Chromosomal abnormalities and microsatellite instability in sporadic endometrial cancer. Eur J Cancer 38, 1802–9 (2002)PubMedCrossRef

13.

L.H. Honoré, J. Hanson, S.E. Andrew, Microsatellite instability in endometrioid endometrial carcinoma: correlation with clinically relevant pathologic variables. Int J Gynecol Cancer 16, 1386–92 (2006)PubMedCrossRef

14.

A. Hirasawa, D. Aoki, J. Inoue et al., Unfavorable prognostic factors associated with high frequency of microsatellite instability and comparative genomic hybridization analysis in endometrial cancer. Clin Cancer Res 9, 5675–82 (2003)PubMed

15.

W. Ju, H.M. Park, S.N. Lee, S.H. Sung, S.C. Kim, Loss of hMLH1 expression is associated with less aggressive clinicopathological features in sporadic endometrioid endometrial adenocarcinoma. J Obstet Gynaecol Res 32, 454–60 (2006)PubMedCrossRef

16.

G.L. Maxwell, J.I. Risinger, A.A. Alvarez, J.C. Barrett, A. Berchuck, Favorable survival associated with microsatellite instability in endometrioid endometrial cancers. Obstet Gynecol 97, 417–22 (2001)PubMedCrossRef

17.

A. Ørbo, K. Eklo, M. Kopp, A semiautomated test for microsatellite instability and its significance for the prognosis of sporadic endometrial cancer in northern Norway. Int J Gynecol Pathol 21, 27–33 (2002)PubMedCrossRef

18.

P. Baldinu, A. Cossu, A. Manca et al., Microsatellite instability and mutation analysis of candidate genes in unselected sardinian patients with endometrial carcinoma. Cancer 94, 3157–68 (2002)PubMedCrossRef

19.

R.F. Caduff, C.M. Johnston, S.M. Svoboda-Newman, E.L. Poy, S.D. Merajver, T.S.I. Frank, Clinical and pathological significance of microsatellite instability in sporadic endometrial carcinoma. Am J Pathol 148, 1671–8 (1996)PubMed

20.

J.M. Pijnenborg, G.C. Dam-de Veen, J. De Haan, M. Van Engeland, P.G. Groothuis, Defective mismatch repair and the development of recurrent endometrial carcinoma. Gynecol Oncol 94, 550–9 (2004)PubMedCrossRef

21.

J.B. Basil, P.J. Goodfellow, J.S. Rader, D.G. Mutch, T.J. Herzog, Clinical significance of microsatellite instability in endometrial carcinoma. Cancer 89, 1758–64 (2000)PubMedCrossRef

22.

C. Bilbao, P.C. Lara, R. Ramirez et al., Microsatellite instability predicts clinical outcome in radiation-treated endometrioid endometrial cancer. Int. J. Radiation Oncology Biol. Phys 76, 9–13 (2010)CrossRef

23.

J.L. Hecht, G. Mutter, Molecular and pathologic aspects of endometrial carcinogenesis. J Clin Oncol 24, 4783–91 (2006)PubMedCrossRef

24.

O. Buhard, N. Suraweera, A. Lectard, Quasimonomorphic mononucleotide repeats for high-level microsatellite instability analysis. Dis Markers 20, 251–257 (2004)PubMed

25.

O. Buhard, F. Cattaneo, Y.F. Wong et al., Multipopulation analysis of polymorphisms in five mononucleotide repeats used to determine the microsatellite instability status of human tumors. J Clin Oncol 24, 241–251 (2006)PubMedCrossRef

26.

R.J. Kurman, R.J. Zaino, H.J. Norris, Endometrial carcinoma: Clinical and pathological features, in Baustein’s Pathology of the Female Genital Tract, ed. by R.J. Kurman, 4th edn. (Springer, New York, 1994), pp. 448–449

27.

K. Søreide, A. Slewa, P.J. Stokkeland et al., Microsatellite instability and DNA ploidy in colorectal cancer: potential implications for patients undergoing systematic surveillance after resection. Cancer 115, 271–82 (2009)PubMedCrossRef

28.

N. Suraweera, A. Duval, M. Reperant et al., Evaluation of tumor microsatellite instability using five quasimonomorphic mononucleotide repeats and pentaplex PCR. Gastroenterology 123, 1804–1811 (2002)PubMedCrossRef

29.

H. Korner, K. Soreide, P.J. Stokkeland, J.A. Söreide, Diagnostic accuracy of serum-carcinoembryonic antigen in recurrent colorectal cancer: a receiver operating characteristic curve analysis. Ann Surg Oncol 14, 417–423 (2007)PubMedCrossRef

30.

N. Horowitz, K. Pinto, D.G. Mutch et al., Microsatellite instability, MLH1 promoter methylation and loss of mismatch repair in endometrial cancer and concomitant atypical hyperplasia. Gynecol Oncol 86, 62–8 (2002)PubMedCrossRef

31.

K. Søreide, E.A. Janssen, H. Søiland, H. Körner, J.P. Baak, Microsatellite instability in colorectal cancer. Br J Surg 93, 395–406 (2006)PubMedCrossRef

32.

S. Popat, R. Hubner, R.S. Houlston, Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 23, 609–618 (2005)PubMedCrossRef

33.

J.M. Cunningham, E.R. Christensen, D.J. Tester et al., Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability. Cancer Res 58, 3455–60 (1998)PubMed

34.

G. Poulogiannis, I. Frayling, M.J. Arends MJ, DNA mismatch repair deficiency in sporadic colorectal cancer and Lynch syndrome, Histopathology (in press)

35.

C. Gurin, M. Federici, L. Kang, J. Boyd, Causes and consequences of microsatellite instability in endomtrial carcinoma. Cancer Res 59, 462–466 (1999)PubMed

36.

M. Kawaguchi, M. Yanokura, K. Bonno et al., Analysis of a correlation between the BRAF V600E mutation and abnormal DNA mismatch repair in patients with sporadic endometrial cancer. Int J. Oncol 34, 1541–7 (2009)PubMed

37.

J. Pallares, A. Velasco, N. Eritja et al., Promoter hypermethylation and reduced expression of RASSF1A are frequent molecular alterations of endometrioid carcinoma. Mod Pathol 21, 691–9 (2008)PubMedCrossRef

38.

S. Kang, J.M. Lee, E.S. Jeon et al., RASSF1A hypermethylation and its inverse correlation with BRAF and/or KRAS mutations in MSI-associated endometrial carcinoma. Int J. Cancer 119, 1316–21 (2006)PubMedCrossRef

39.

G. Moreno-Bueno, D. Hardission, C. Sanchez et al., Abnormalities of the APC/bata- catenin pathway in endometrial cancer. Oncogene 21, 7981–90 (2002)PubMedCrossRef

40.

D. Furlan, I. Carnevali, B. Marcomini et al., The high frequency of de novo promoter methylation in synchronous primary endometrial and ovarian carcinomas. Clin. Cancer Res 12, 3329–36 (2006)PubMedCrossRef

41.

M. Arafa, F. Kridelka, V. Mathias et al., High frequency of RASSF1A and RARb2 gene promoter methylation in morphologically normal endometrium adjacent to endometrioid adenocarcinoma. Histopathology 53, 525–32 (2008)PubMed

42.

Y. Suehiro, T. Okada, K. Anno et al., Aneuploidy predicts outcome in patients with endometrial carcinoma and is related to lack of CDH13 hypermethylation. Clin Cancer Res 14, 3354–61 (2008)PubMedCrossRef

43.

H. Lagarda, L. Catasus, R. Arguelles, X. Matias-Guiu, J. Prat, K-ras mutations in endometrial carcinomas with microsatellite instability. J Pathol 193, 193–9 (2001)PubMedCrossRef

44.

A. Steinbakk, I. Skaland, E. Gudlaugsson et al., The prognostic value of molecular biomarkers in tissue removed by curettage from FIGO stage 1 and 2 endometrioid type endometrial cancer. Am J Obstet Gynecol 200, 78.e1–78.e8 (2009)CrossRef

Title: High frequency microsatellite instability has a prognostic value in endometrial endometrioid adenocarcinoma, but only in FIGO stage 1 cases
Authors: Anita Steinbakk
Anais Malpica
Aida Slewa
Einar Gudlaugsson
Emiel A. M. Janssen
Mark Arends
Arnold Jan Kruse
Yu Yinhua
Weiwei Feng
Jan P. Baak
Publication date: 01-10-2011
Publisher: Springer Netherlands
Published in: Cellular Oncology / Issue 5/2011
Print ISSN: 2211-3428
Electronic ISSN: 2211-3436
DOI: https://doi.org/10.1007/s13402-011-0040-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objectives

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 5/2011

Gene copy number variation in male breast cancer by aCGH

Ultra-fast processing of gigapixel Tissue MicroArray images using High Performance Computing

Erratum to: ACP, volume 33, issues 1, 3–4 and 5–6, 2010

Gene expression of somatostatin receptor subtypes SSTR2a, SSTR3 and SSTR5 in peripheral blood of neuroendocrine lung cancer affected patients

p21/waf1 and smooth-muscle actin α expression in stromal fibroblasts of oral cancers

A protein profile study to discriminate CIN lesions from normal cervical epithelium

Keynote webinar | Spotlight on antibody–drug conjugates in cancer